retatrutide safety trials ⚠️ “RETA” is NOT an approved weight-loss medication. Social media is full of “RETA” offers—but here's what you should know. is a promising investigational medicine developed by Eli Lilly. The Phase This weight-loss drug hasn't been

HuQZhangYLouHOuZLiuJDuanWet al

In the ever-evolving landscape of biochemical research, compounds like 5-Amino-1MQ have truly captured the scientific community's keen attention

For Continuing Therapy If you are already on Zepbound: A renewal PA is required at 29 weeks After that, PAs are required every 12 months You must generally demonstrate a 5% reduction in weight from your baseline Important Clarification for Members Switching from Another GLP-1 If you are continuing therapy on a GLP-1 weight loss medication other than Zepbound, such as Wegovy: even if your BMI is now below 30, if you have lost 5% or more of your baseline weight, you may still meet prior authorization criteria for Zepbound under continuation-of-therapy guidelines

n = 4,668) or placebo ( n = 4,672), with both groups also receiving standard care (treatment period: 3.55 years)